SeekingAlpha · Aug 29, 2026
Insulet Corporation: Strong Growth Meets A New Execution Problem
Insulet Corporation delivered strong Q2 2026 results with 23.5% revenue growth, strong customer additions, and solid profitability. Click for more on PODD.
NASDAQ · PODD
Insulet Corporation
Healthcare · Medical - Devices
$145.13
Up+$3.45 (+2.37%)
Updated Aug 31, 2026, 3:13 PM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 20.7B
- P/E ratio
- 84.09
- Dividend yield
- 0.00%
- 52-week range
- $126.40 – $317.34
- Volume
- 1.04M
- Avg. volume
- 653.12K
Price performance
PODD price history
1M range · 20 trading sessions · Daily adjusted prices
PODD closed at $145.13 after 20 trading sessions, down 14.48% for the selected period.
- Last close
- $145.13
- Period change
- -14.48%
- Period low
- $133.26
- Period high
- $169.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $144.20 | $146.67 | $143.805 | $145.13 | 1.04M |
| Aug 27, 2026 | $142.96 | $144.60 | $140.98 | $143.41 | 1.34M |
| Aug 26, 2026 | $141.27 | $144.64 | $141.23 | $143.38 | 1.42M |
| Aug 25, 2026 | $145.28 | $146.095 | $141.78 | $143.05 | 1.93M |
| Aug 24, 2026 | $151.17 | $151.75 | $145.15 | $145.42 | 1.57M |
| Aug 21, 2026 | $146.87 | $150.20 | $145.035 | $148.16 | 903.61K |
| Aug 20, 2026 | $151.74 | $152.685 | $146.67 | $146.87 | 1.21M |
| Aug 19, 2026 | $148.00 | $155.17 | $147.955 | $151.51 | 1.31M |
| Aug 18, 2026 | $139.91 | $149.335 | $139.45 | $148.03 | 1.62M |
| Aug 17, 2026 | $141.32 | $142.13 | $138.275 | $139.70 | 1.95M |
| Aug 14, 2026 | $146.98 | $147.1707 | $143.02 | $143.34 | 789.6K |
| Aug 13, 2026 | $145.06 | $146.825 | $143.12 | $146.44 | 1.37M |
| Aug 12, 2026 | $142.00 | $145.59 | $138.70 | $145.06 | 1.57M |
| Aug 11, 2026 | $142.45 | $145.16 | $141.00 | $144.70 | 1.25M |
| Aug 10, 2026 | $140.55 | $143.94 | $140.34 | $142.85 | 1.51M |
| Aug 7, 2026 | $138.00 | $142.22 | $136.46 | $141.17 | 1.59M |
| Aug 6, 2026 | $130.90 | $139.48 | $130.11 | $139.30 | 3.25M |
| Aug 5, 2026 | $128.00 | $138.41 | $126.40 | $133.26 | 7.18M |
| Aug 4, 2026 | $166.34 | $170.99 | $164.31 | $166.82 | 1.75M |
| Aug 3, 2026 | $168.56 | $172.105 | $166.655 | $169.70 | 1.41M |
Latest PODD news
The latest Smart Investors Daily articles mentioning PODD.
Stock researchCompany · Overview
PODD research
Overview
Company profile and research snapshot.
Company profile
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $386.43
- Implied upside
- —
- Analysts
- 33
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Leerink Partners | Market Perform | — |
| Aug 6, 2026 | Benchmark | Buy | — |
| Aug 6, 2026 | Bernstein | Outperform | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | TD Cowen | Hold | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 27, 2026
Insulet (NASDAQ:PODD): Growth at a Reasonable Valuation
Insulet Corp (PODD) fits the affordable growth screen: strong EPS and revenue growth, reasonable valuation, and overall solid profitability.
ChartMill · Aug 24, 2026
These S&P500 stocks are moving in today's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.
Benzinga · Aug 24, 2026
President and CEO Of Insulet Purchased $162K In Stock
Disclosed in the latest SEC filing, a significant insider purchase on August 24, involves Ashley McEvoy, President and CEO at Insulet (NASDAQ:PODD). What Happened: McEvoy made a significant move by purchasing 1,100
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
